GlassScriptPhysician profile
Benjamin W Raile
NPI 1093979981
$11,481.83
in general payments reported to CMS, 2019-2025
41 companies · $2,682 in 2025
The $2,682 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $823 · 2020: $163 · 2021: $897 · 2022: $1,721 · 2023: $2,169 · 2024: $3,028 · 2025: $2,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,878.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,592.11 | 2019-2025 | |
| Janssen Biotech, INC. | $1,441.79 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,434.30 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $865.42 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $702.67 | 2019-2025 | Livdelzi |
| Madrigal Pharmaceuticals | $501.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $474.28 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $378.88 | 2022-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $359.64 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $273.21 | 2019-2025 | |
| Braintree Laboratories, INC. | $211.55 | 2019-2024 | Suflave, Sutab |
| E.R. Squibb & Sons, L.L.C. | $209.84 | 2021-2023 | Zeposia |
| Genzyme Corporation | $202.16 | 2023-2025 | |
| Lilly USA, LLC | $200.26 | 2024-2025 | Omvoh |
| Becton, Dickinson and Company | $199.68 | 2025 | Phasix Mesh |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Raile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.